Clinical characteristics influencing the effectiveness of metformin on Japanese type 2 diabetes receiving sulfonylureas - PubMed (original) (raw)
doi: 10.1507/endocrj.k06-162. Epub 2007 Feb 16.
Affiliations
- PMID: 17303931
- DOI: 10.1507/endocrj.k06-162
Free article
Clinical characteristics influencing the effectiveness of metformin on Japanese type 2 diabetes receiving sulfonylureas
Setsuko Tomioka et al. Endocr J. 2007 Apr.
Free article
Abstract
In this study, we described the effectiveness of metformin on Japanese type 2 diabetes patients receiving sulfonylureas and the clinical characteristics of the patients whose glycemic control were significantly improved with metformin administration. Our results showed that the reduction of glycohemoglobin (HbA1C), serum concentration of total cholesterol, and diastolic blood pressure was statistically significant through the administration of metformin. The clinical characteristics of the patients who responded to metformin therapy exhibited lower systolic blood pressure in addition to higher HbA1C value just before administration of metformin when compared with DeltaHbA1C (HbA1C 6 months after administration of metformin--HbA1C before administration of metformin). Moreover, effectiveness of metformin was weakened, in comparison with non-hypertensive patients, even though the blood pressure of hypertensive patients was reduced to normal range by medication with antihypertensive drugs. But average reduction of HbA1C level of hypertensive patients without antihypertensive medications was smaller than those of patients with high blood pressure with such medication. These results suggested that high blood pressure and hypertension phenotype itself were suppressive factors of metformin but antihypertensive therapy itself enhanced the effectiveness of metformin regardless of the improvement of blood pressure.
Similar articles
- Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Ridderstråle M, et al. Cardiovasc Diabetol. 2013 Sep 5;12:129. doi: 10.1186/1475-2840-12-129. Cardiovasc Diabetol. 2013. PMID: 24007456 Free PMC article. Clinical Trial. - Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
Gavin LA, Barth J, Arnold D, Shaw R. Gavin LA, et al. Endocr Pract. 2000 Jul-Aug;6(4):305-10. doi: 10.4158/EP.6.4.305. Endocr Pract. 2000. PMID: 11242607 - Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, Xu L, Hanson ME, Engel SS, Shankar RR. Ba J, et al. J Diabetes. 2017 Jul;9(7):667-676. doi: 10.1111/1753-0407.12456. Epub 2016 Sep 13. J Diabetes. 2017. PMID: 27502307 Clinical Trial. - UKPDS and beyond: into the next millennium. United Kingdom Prospective Diabetes Study.
Krentz AJ. Krentz AJ. Diabetes Obes Metab. 1999 Jan;1(1):13-22. doi: 10.1046/j.1463-1326.1999.00009.x. Diabetes Obes Metab. 1999. PMID: 11221807 Review. No abstract available. - Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.
Gross JL, Kramer CK, Leitão CB, Hawkins N, Viana LV, Schaan BD, Pinto LC, Rodrigues TC, Azevedo MJ; Diabetes and Endocrinology Meta-analysis Group (DEMA). Gross JL, et al. Ann Intern Med. 2011 May 17;154(10):672-9. doi: 10.7326/0003-4819-154-10-201105170-00007. Ann Intern Med. 2011. PMID: 21576535 Review.
Cited by
- Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis.
Guo L, Chang B, Chen L, Yang L, Liu Y, Feng B, He Q. Guo L, et al. Sci Rep. 2021 Feb 18;11(1):4131. doi: 10.1038/s41598-021-83410-x. Sci Rep. 2021. PMID: 33602996 Free PMC article. Clinical Trial. - Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.
Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, Defronzo R, Cefalu WT. Raz I, et al. Diabetes Care. 2013 Jun;36(6):1779-88. doi: 10.2337/dc13-0512. Diabetes Care. 2013. PMID: 23704680 Free PMC article. - Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Salpeter SR, et al. Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4. Cochrane Database Syst Rev. 2010. PMID: 20393934 Free PMC article. Review.